F18-FDG-PET用于复发性分化型甲状腺癌：一项系统的Meta分析。
F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis.
作者信息
Haslerud Torjan, Brauckhoff Katrin, Reisæter Lars, Küfner Lein Regina, Heinecke Achim, Varhaug Jan Erik, Biermann Martin
机构信息
Nuclear Medicine/PET-Center, Department of Radiology, Haukeland University Hospital, Bergen, Norway.
Section for Endocrine Surgery, Haukeland University Hospital, Bergen, Norway.
出版信息
Acta Radiol. 2016 Oct;57(10):1193-200. doi: 10.1177/0284185115594645. Epub 2015 Jul 9.
BACKGROUND
Positron emission tomography (PET) with fluor-18-deoxy-glucose (FDG) is widely used for diagnosing recurrent or metastatic disease in patients with differentiated thyroid cancer (DTC).
PURPOSE
To assess the diagnostic accuracy of FDG-PET for DTC in patients after ablative therapy.
MATERIAL AND METHODS
A systematic search was conducted in Medline/PubMed, EMBASE, Cochrane Library, Web of Science, and Open Grey looking for all English-language original articles on the performance of FDG-PET in series of at least 20 patients with DTC having undergone ablative therapy including total thyroidectomy. Diagnostic performance measures were pooled using Reitsma's bivariate model.
RESULTS
Thirty-four publications between 1996 and 2014 met the inclusion criteria. Pooled sensitivity and specificity were 79.4% (95% confidence interval [CI], 73.9-84.1) and 79.4% (95% CI, 71.2-85.4), respectively, with an area under the curve of 0.858.
CONCLUSION
F18-FDG-PET is a useful method for detecting recurrent DTC in patients having undergone ablative therapy.
背景
氟-18-脱氧葡萄糖（FDG）正电子发射断层扫描（PET）广泛用于诊断分化型甲状腺癌（DTC）患者的复发或转移性疾病。
目的
评估FDG-PET对接受消融治疗后的DTC患者的诊断准确性。
材料与方法
在Medline/PubMed、EMBASE、Cochrane图书馆、科学网和Open Grey中进行系统检索，查找所有关于FDG-PET在至少20例接受包括全甲状腺切除术在内的消融治疗的DTC患者系列中的表现的英文原创文章。使用Reitsma双变量模型汇总诊断性能指标。
结果
1996年至2014年间的34篇出版物符合纳入标准。汇总敏感性和特异性分别为79.4%（95%置信区间[CI]，73.9 - 84.1）和79.4%（95%CI，71.2 - 85.4），曲线下面积为0.858。
结论
F18-FDG-PET是检测接受消融治疗的患者复发性DTC的有用方法。
Zotero 插件